Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/122884
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Early Management of CML |
Author: | Shanmuganathan, N. Hughes, T.P. |
Citation: | Current Hematologic Malignancy Reports, 2019; 14(6):480-491 |
Publisher: | Springer (part of Springer Nature) |
Issue Date: | 2019 |
ISSN: | 1558-8211 1558-822X |
Statement of Responsibility: | Naranie Shanmuganathan, Timothy P. Hughes |
Abstract: | PURPOSE OF REVIEW:The marked improvement in clinical outcomes for patients with chronic myeloid leukaemia (CML) can be solely attributed to the introduction of targeted therapies against the fusion oncoprotein, BCR-ABL1. However, patient responses, although generally positive, remain heterogenous. Careful drug selection, ensuring the optimal TKI, is chosen for each patient and involves a complex decision process which incorporates consideration of numerous factors. RECENT FINDINGS:For some patients, with disease characteristics that indicate adverse intrinsic disease biology, more potent BCR-ABL1 inhibition is often appropriate, whereas other patients with major co-morbidities will benefit from a less aggressive approach to avoid life-shortening toxicities. For the vast majority of patients, the long-term goal of therapy will be the achievement of a deep molecular response and subsequent treatment-free remission and this consideration will play a large part in the drug selection process. We explore early management of CML, from the first presentation through to frontline therapy selection. |
Keywords: | Deep molecular responses Drug toxicity TKI Treatment-free remission |
Rights: | © Springer Science+Business Media, LLC, part of Springer Nature 2019. |
DOI: | 10.1007/s11899-019-00550-8 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1135949 |
Published version: | http://dx.doi.org/10.1007/s11899-019-00550-8 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.